Drug Profile


Alternative Names: BFBTS; FLP

Latest Information Update: 20 Apr 2016

Price : $50

At a glance

  • Originator ACEA Biosciences
  • Class Antineoplastics; Fluorobenzenes; Sulfides
  • Mechanism of Action Tubulin polymerisation inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • On Fast track

    Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.

  • New Molecular Entity Yes

Highest Development Phases

  • No development reported Lung cancer; Solid tumours

Most Recent Events

  • 20 Apr 2016 Chemical structure information added
  • 20 Apr 2016 No recent reports on development identified - Phase-I for Solid tumours & Lung cancer (Late-stage disease) in China (IV)
  • 24 May 2011 Phase-I clinical trials in Solid tumours and Lung cancer (late-stage) in China (IV)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top